QuantHealth announced it has raised a $15 million series A funding round today (August 22) for its clinical simulator that can predict how a patient will respond to treatment in a clinical trial.
Another company OSP was lucky enough to catch up with at DIA Global in Boston this year, was well-established generative artificial intelligence (AI) software company, Yseop.
A partnership between technology company Fluree and Vitality TechNet is a ‘groundbreaking effort’ to shorten timelines within the drug discovery process.
A company that ‘translates science into survival’ by developing new therapies has completed its acquisition of a technology company leading in artificial intelligence (AI) and machine learning (ML).
The US Food and Drug Administration (FDA) has today (July 31) given clearance via its 510(k) process to one of the artificial intelligence solutions cleared for colonoscopy.
The U.S. startup Readout AI has closed a pre-seed financing round to fuel the development of an artificial intelligence (AI)-based tool to speed up data analysis in clinical trials.
The Israeli company Galmed Pharmaceuticals is deploying artificial intelligence (AI) tools developed by the U.S. company OnKai to help carry out clinical trials of a rare disease treatment in communities that have low access to healthcare.
Updated guidelines for risk-based quality management (RBQM) are much more than just for monitoring purposes and can show quality by design concepts, save immeasurable time on manpower and shows there has been a complete mindset shift within the last 15...
With the FDA issuing guidance on more diversity within clinical trials, it is a subject many companies are being encouraged to focus on, each with their own approach.
Everybody seems to be talking about artificial intelligence at the moment. Some are fascinated, others afraid and a few might worry for their jobs. However, for the pharmaceutical industry, it is said to be completely transforming the landscape.
Helmholtz Munich, part of Germany’s biggest research organization, the Helmholtz Association, alongside DDN, the world’s largest data storage company have been selected as a winner of the 2023 AI Breakthrough Awards, for best AI-based solution for life...
With generative AI continuing to create a buzz, OSP took the opportunity to speak to Indegene, a digital-first, life sciences commercialization company that helps biopharmaceutical, emerging biotech and medical device companies develop products. Talking...
Exscientia plc has announced a sixth molecule has been created through its generative artificial intelligence (AI) platform to enter clinical stage. It is the third clinical molecule from a collaboration with Sunitomo Pharma to enter phase 1 trials.
Cognizant has announced a platform that can use it consulting, advisory, ecosystem partnership along with digital studios and industry knowledge to help its clients transition to generative artificial intelligence (AI).
Helmholtz Munich, one of Germany’s 19 research centers, that develops future solutions and technologies has selected DataDirect Networks (DDN) to accelerate its artificial intelligence (AI) driven discoveries.
Aerona Clinical is a medium sized pharmaceutical company, represented not only in the United Kingdom, but in Europe, and with a global reach. The company has been operating in this environment in the pharma industry for 15 to 20 years.
Unifying medicinal development processes and data within a connected technology ecosystem will enhance collaboration, two partnering companies using a development cloud have said.
OSP spoke to Vladamir Penkrat, head of safety and regulatory and Shuba Rao a senior director at Indegene, a life sciences digital company about a paper they recently published called 'Challenges and Future of PV Compliance' about the direction...
A powerful tool that could capture abdominal aortic aneurysms (AAA) and refer those at risk is the first to be given clearance by the US Food and Drink Administration (FDA).
Challenging target profiles can be targeted more efficiently than traditional drug discovery using Exscientia’s AI-driven precision design platform, its CEO says.
Software that can enhance stroke patient outcomes by decreasing detection time and reducing disabilities is the first CE marked device that can help find large vessel occlusions (LVOs).
The partners announce that they will combine to use artificial intelligence to improve the identification and enrolment of patients for clinical trials.
Research emerging from the University of Toronto found that using machine learning models was able to guide the design of long-acting drug formulations.
The partners have come together to apply artificial intelligence to phenotypic drug screening, with the aim of developing therapies in different therapeutics areas.
As the year draws to a close, Outsourcing-Pharma caught up with some senior executives for a three-part series looking back on an eventful 2022, and look ahead to 2023.
First ever longtudinal study from ALS non-profit focuses on finding digital biomarkers using IBM Research’s proprietary AI. The study leverages audiovisual samples from participants with ALS, genetic carriers, and caregivers.
Partnership between Massive Bio and Azra AI extends clinical care teams bandwidth to place cancer patients in trials while eliminating unconscious bias.
Massive Bio partners with Perthera.ai to improve cancer clinical trial enrolment through the use of AI technology to connect oncologists and patients with biomarker-based therapy options.
Indegene’s partnership with Tealium leverages AI-driven data strategy for life sciences companies to navigate the industry’s connected technology ecosystem.
OMEC.AI is the first startup to emerge from the alliance of pharma companies and investors that created AION Labs, and will focus on improving the efficacy and safety of drug candidates.
Compliance data generated from the documentation of interactions with HCPs can be leveraged using AI and ML to the benefit of stakeholders across the industry, according to IQVIA.
Pfizer and CytoReason have been partnered on artificial intelligence and machine learning technologies for drug discovery and development since 2019. The latest deal brings the companies closer.
A fleet of legal professionals offers advice and perspective on important considerations when harnessing artificial intelligence and real-world evidence.
The pharma company’s collaboration with the drug discovery specialist involves using artificial intelligence to discover and develop up to five drug targets.
The pharmaceutical company and the artificial intelligence pathology specialist will focus on translational research in oncology, fibrosis, and immunology.
The AI and QC specialists have joined to use AI and QC in order to discover biological pathways relevant to the treatment of triple-negative breast cancer.
An expert from the clinical insight specialist shares how predictive analytics could reveal info about medication adherence, disease progression, and more.
A leader from pharmaceutical firm Astellas discusses how the company has put to use a discovery platform that combines human expertise, AI, and robotics.
Epistemic AI, Cincinnati Children’s Hospital Medical Center, and Boomer Esiason Foundation are working together to advance research into the rare disease.
